



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Itai BAB et al.

Appl. No. 10/766,527

Confirmation No. 2819

Filed: January 29, 2004

For: OSTEOGENIC GROWTH
OLIGOPEPTIDES AS
STIMULANTS OF
HEMATOPOIESIS

Art Unit: 1646

Examiner: T. Heard

Atty. Docket No. 31949-200571

Customer No.

26694

PATENT TRADEMARK OFFICE

Information Disclosure Statement

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement in order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO SB/08 and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

In view of the above, all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

03/01/2007 JADD01 00000001 220261 10766527
02 FC:1006 100.00 DA

Applicants: Itai BAB et al.
Appl. No. 10/766,527

Please charge any necessary fee or credit any overpayment in connection with this
Information Disclosure Statement to Deposit Account No. 22-0261.


Respectfully submitted,

Date: 2/28/07



Ann S. Hobbs, Ph.D.
Registration No. 36,830
VENABLE LLP
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 344-4000
Telefax: (202) 344-8300
ashobbs@venable.com

832229



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/766,527
		Filing Date	January 29, 2004
		First Named Inventor	Itai BAB et al.
		Art Unit	1646
		Examiner Name	T. Heard
		Attorney Docket Number	31949-200571
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Exhibit A: Clark, S.C et al., ;The human hematopoietic colony stimulating factors Figure 22; page 95, Science, 1987: 263:1229-1237.	
	CB	Exhibit B: To, L.B. et al., "The Biology and Clinical Uses of Blood Stem Cells, The Journal of the American Society of Hematology, April 1, 1997, Vol. 89, No. 7, pp 2233-2258	
	CC	Exhibit C: Fu S., et al., Mobilization of Hematopoietic Stem Cells, Blood Reviews (2000) 14, 205-218	
	CD	Exhibit D: Lapidot, Tsvee t al., Current Understanding Of Stem Cell Mobilization: The roles of Chemokines, Proteolytic Enzymes, Adhesion Molecules, Cytokines, and Stromal Cells, Experimental Hematology 30 (200) 973-981	
	CE	Exhibit E: Voermans, Carlijn et al., In Vitro Migratory Capacity of CD34+ Cells is Related to Hematopoietic Recovery After Autologous Stem Cell Transplantation, Blood, Feb. 2, 1001, Vol. 97, No. 3, pages 799-804	
	CF	Exhibit F: Schmitz, N., et al., "Allogeneic Bone Marrow Transplantation vs Filgrastim-Mobilised Peripheral Blood Progenitor Cell Transplantation in Patients with Early Leukaemia: First Results of a Randomised Multicentre Trial of The European Group for Blood and Marrow Transplantation, Bone Marrow Transplantation 9(1998), Vol. 21, 995-1003	
	CG	Exhibit G: Aversa, Franco, et al., Treatment of High-Risk Acute Leukemia With T-Cell-Depleted Stem Cells From Related Donors with One Fully Mismatched HLA Haplotype, New England Journal of Medicine, Oct. 22, 1998, 1196-1193	
	CH	Exhibit H: Oral Abstracts, ISCT 1003; Abstracts 165-168, page 81	
	CI	Exhibit I: Keating, S., et al., The Stem Cell Mobilizing Capacity of Patients with Acute Myeloid Leukemia In Complete Remission Correlates with Relapse risk: Results of the EORTC-GIMEMA AML-10 Trial, Leukemia (2003), 17, 60-67	
	CJ		
	CK		
	CL		
	CM		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
803759

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--